GSA Capital Partners LLP Purchases 35,571 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

GSA Capital Partners LLP grew its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 179.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,359 shares of the company’s stock after purchasing an additional 35,571 shares during the period. GSA Capital Partners LLP’s holdings in Protagonist Therapeutics were worth $1,602,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Kynam Capital Management LP lifted its stake in Protagonist Therapeutics by 10.2% during the fourth quarter. Kynam Capital Management LP now owns 2,004,875 shares of the company’s stock worth $45,972,000 after purchasing an additional 186,218 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at about $4,606,000. Superstring Capital Management LP bought a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at about $8,694,000. Opaleye Management Inc. bought a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at about $2,584,000. Finally, Walleye Capital LLC lifted its stake in shares of Protagonist Therapeutics by 209.3% in the 3rd quarter. Walleye Capital LLC now owns 133,816 shares of the company’s stock valued at $2,232,000 after acquiring an additional 90,555 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In related news, CFO Asif Ali sold 1,234 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the transaction, the chief financial officer now owns 37,163 shares in the company, valued at approximately $933,162.93. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $35.19, for a total transaction of $1,231,650.00. Following the transaction, the chief executive officer now owns 515,415 shares in the company, valued at approximately $18,137,453.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Asif Ali sold 1,234 shares of the company’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total value of $30,985.74. Following the transaction, the chief financial officer now owns 37,163 shares in the company, valued at approximately $933,162.93. The disclosure for this sale can be found here. Insiders have sold a total of 44,234 shares of company stock worth $1,542,636 in the last 90 days. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Price Performance

NASDAQ:PTGX traded down $0.08 during mid-day trading on Wednesday, reaching $34.42. 92,894 shares of the company’s stock traded hands, compared to its average volume of 795,620. Protagonist Therapeutics, Inc. has a 12-month low of $13.72 and a 12-month high of $35.96. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of 14.14 and a beta of 2.13. The company has a 50 day moving average price of $31.23 and a 200-day moving average price of $28.38.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $3.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.75. The business had revenue of $254.95 million for the quarter, compared to analysts’ expectations of $300.00 million. As a group, analysts forecast that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PTGX shares. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a research note on Friday, June 14th. JMP Securities reissued a “market outperform” rating and issued a $45.00 target price on shares of Protagonist Therapeutics in a research note on Monday, June 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.